Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective faithfully but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing picture in the Uptick Newswire job interview that I came away with a bad impression of the business.

Irony of irony, my poor impression of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise as well as linked intellectual property from Progenics to CytoDyn, and approximately 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) plus the very first new drug program approval ($5 million), and even royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and many indications, it has this individual remedy in addition to a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations in addition to multiple publications.

Could it all be smoke cigarettes and mirrors? That is a question I have been asking myself through the really beginning of the interest of mine in this company. Judging by way of the multiples of thousands of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *